PT-141 (Bremelanotide) Dosing in Hepatic Impairment

How Bremelanotide Works: Melanocortin Receptor Activation

Bremelanotide is a synthetic cyclic heptapeptide that activates melanocortin-4 receptors (MC4R) in the central nervous system. This activation modulates neural pathways involved in sexual desire, distinct from the vascular mechanism of PDE5 inhibitors like sildenafil. The drug received FDA approval in June 2019 under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women [1].

Mechanism at the Receptor Level

MC4R receptors are expressed in the hypothalamus, limbic system, and medial preoptic area. Bremelanotide binds these receptors as a nonselective agonist, also showing activity at MC1R and MC3R subtypes [2]. The downstream signaling cascade involves cyclic AMP elevation and activation of oxytocin and dopamine pathways that regulate sexual arousal and motivation.

Why This Matters for Liver Disease

Unlike drugs that require hepatic bioactivation, bremelanotide arrives at its target receptors as the active compound. No prodrug conversion is needed. This pharmacologic feature is directly relevant to hepatic impairment because the drug's efficacy does not depend on liver enzyme function for activation. The concern in liver disease shifts instead to clearance kinetics and the potential for prolonged exposure [3].

The RECONNECT phase 3 trials (N=1,247 combined across RECONNECT-1 and RECONNECT-2) demonstrated that bremelanotide 1.75 mg significantly improved the number of satisfying sexual events and reduced distress associated with low sexual desire compared to placebo over 24 weeks [1]. These trials enrolled women without significant hepatic disease, leaving the hepatic impairment question to dedicated pharmacokinetic studies.

Pharmacokinetics in Hepatic Impairment: What the Data Show

The FDA-approved prescribing information for Vyleesi includes pharmacokinetic data from a dedicated hepatic impairment study. Bremelanotide was administered as a single 1.75 mg subcutaneous dose to subjects with mild (Child-Pugh A) and moderate (Child-Pugh B) hepatic impairment, then compared to matched healthy controls [3].

Key Pharmacokinetic Findings

In subjects with mild hepatic impairment, the area under the curve (AUC) and maximum concentration (Cmax) of bremelanotide were comparable to those in healthy volunteers. The geometric mean ratios fell within standard bioequivalence bounds (80% to 125%), indicating no clinically meaningful difference in drug exposure.

Moderate hepatic impairment produced a modest increase in AUC (approximately 30% higher than controls), but this change did not cross the threshold that would require dose modification based on the drug's established safety margin at the 1.75 mg dose [3]. The half-life of bremelanotide is approximately 2.7 hours in healthy subjects, and this was not substantially prolonged in the moderate impairment group.

Severe Hepatic Impairment: The Data Gap

No pharmacokinetic study has been conducted in patients with severe hepatic impairment (Child-Pugh C). The FDA label explicitly notes this gap. Given that severe liver disease alters protein binding, reduces splanchnic blood flow, and may impair peptide hydrolysis, extrapolation from the mild-to-moderate data is unreliable.

Patients with Child-Pugh C cirrhosis often have portal hypertension, ascites, and altered drug distribution volumes. For a peptide like bremelanotide that can transiently raise blood pressure (mean systolic increase of 6 mmHg, with some patients experiencing rises above 20 mmHg), the combination of hemodynamic instability and unpredictable drug exposure creates a risk profile that outweighs potential benefit [3].

Clearance Pathways: Why Bremelanotide Is Not Primarily Liver-Dependent

Understanding why bremelanotide tolerates mild-to-moderate liver dysfunction requires a closer look at its elimination. The drug is a cyclic peptide, not a small molecule metabolized by cytochrome P450 enzymes. Its clearance occurs through multiple pathways.

Peptide Hydrolysis and Renal Excretion

Bremelanotide undergoes hydrolysis by nonspecific peptidases distributed throughout the body, not confined to hepatocytes. Approximately 64.8% of a subcutaneous dose is recovered in urine, with both intact drug and hydrolysis products contributing to renal elimination [3]. This renal-predominant excretion profile explains why hepatic impairment has a limited effect on overall drug exposure.

CYP Enzyme Independence

In vitro studies confirmed that bremelanotide does not inhibit or induce major CYP450 isoforms (1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 3A4) at clinically relevant concentrations [3]. It is neither a substrate nor a significant modulator of these enzymes. For patients with hepatic impairment who are often on multiple medications metabolized by CYP pathways, this lack of interaction potential is a practical advantage.

Drug-Drug Interaction Considerations in Liver Disease

Patients with liver disease frequently take medications such as beta-blockers (propranolol, nadolol) for portal hypertension, diuretics (spironolactone, furosemide) for ascites, and lactulose for hepatic encephalopathy. The FDA labeling notes one specific interaction: bremelanotide slowed gastric emptying in a clinical study, which reduced the Cmax of orally administered naltrexone by 42% and indomethacin by 28% [3]. This gastroparesis effect could alter the absorption of co-administered oral medications, a particularly important consideration in patients already experiencing delayed gastric motility from liver disease.

Blood Pressure Effects: Heightened Relevance in Liver Disease

Bremelanotide's transient pressor effect is its most clinically significant cardiovascular concern, and hepatic impairment amplifies the context in which this effect matters.

Trial Data on Blood Pressure

In the RECONNECT trials, bremelanotide 1.75 mg increased systolic blood pressure by an average of 6 mmHg and diastolic pressure by 3 mmHg, with peak effect occurring approximately 2 to 3 hours post-dose [1]. Individual responses varied. Some patients recorded systolic increases exceeding 20 mmHg. Blood pressure returned to baseline within 12 hours in most subjects.

Portal Hypertension and Hemodynamic Fragility

Patients with cirrhosis and portal hypertension exist in a hyperdynamic circulatory state. Cardiac output is elevated, systemic vascular resistance is low, and mean arterial pressure is often at the lower boundary of normal. A drug-induced blood pressure spike in this setting could destabilize compensated cirrhosis or trigger complications in patients with varices.

The Endocrine Society and AACE do not have specific guidelines addressing melanocortin agonist use in cirrhotic patients [4]. The practical recommendation from the FDA labeling is to use bremelanotide with caution in patients with cardiovascular disease, and by extension, clinicians should apply similar caution to patients with hemodynamically significant liver disease [3].

Monitoring Recommendations

For patients with Child-Pugh A or B hepatic impairment who receive bremelanotide:

• Check blood pressure before the first dose and 1 to 2 hours after administration
• Assess for nausea, which occurred in 40% of trial participants and may be more pronounced in patients with hepatic congestion or gastroparesis
• Review the medication list for drugs with narrow therapeutic indices that could be affected by slowed gastric emptying
• Repeat liver function tests (ALT, AST, bilirubin, albumin) if the patient transitions from as-needed use to more frequent dosing patterns

Nausea Management in Hepatic Impairment

Nausea is the most common adverse effect of bremelanotide, reported in 40.0% of patients receiving the 1.75 mg dose versus 1.3% on placebo in the RECONNECT program [1]. For patients with liver disease, nausea management requires special attention.

Why Nausea May Be Worse

Hepatic impairment is independently associated with gastroparesis, nausea, and reduced appetite. Bremelanotide's central mechanism of action (MC4R activation in the brainstem area postrema) adds a pharmacologic nausea signal on top of the baseline hepatic nausea. The combination can be debilitating enough to limit adherence.

Practical Approaches

Ondansetron 4 mg orally, taken 30 minutes before the bremelanotide dose, may reduce nausea severity. Ondansetron is metabolized by CYP3A4 and CYP1A2, so doses should be capped at 8 mg per day in patients with moderate hepatic impairment per its own labeling [5]. Metoclopramide is generally avoided in advanced liver disease due to its hepatic metabolism and risk of extrapyramidal effects in patients with reduced clearance.

Eating a light meal 1 to 2 hours before the bremelanotide injection can reduce nausea intensity. An empty stomach accelerates peptide absorption and may produce a sharper Cmax, worsening the nausea signal.

Off-Label Use in Erectile Dysfunction: Liver Considerations

Bremelanotide is FDA-approved only for HSDD in premenopausal women, but off-label use for male erectile dysfunction has been documented in clinical practice. Earlier phase 2 trials studied intranasal bremelanotide in men with ED and demonstrated erectile responses, though the intranasal formulation was not pursued due to blood pressure concerns at higher doses [6].

Relevance to Male Patients with Liver Disease

Men with cirrhosis have high rates of sexual dysfunction. Hypogonadism occurs in 40% to 90% of men with cirrhosis, driven by increased sex hormone-binding globulin (SHBG), reduced hepatic clearance of estrogens, and direct gonadal toxicity from alcohol or iron overload [7]. PDE5 inhibitors are used cautiously in this population because sildenafil and tadalafil are extensively metabolized by hepatic CYP3A4, and their clearance is reduced 2- to 3-fold in Child-Pugh B cirrhosis.

Bremelanotide's CYP-independent clearance makes it a pharmacokinetically simpler option in this context. The 1.75 mg dose studied in women has been the reference dose in off-label male use, though no randomized controlled trial has evaluated bremelanotide specifically in men with hepatic impairment. Prescribers pursuing this off-label path should apply the same Child-Pugh-based framework: acceptable in A and B with monitoring, avoid in C.

Skin Hyperpigmentation: A Unique Concern in Liver Disease

Bremelanotide's activity at MC1R receptors in melanocytes can cause focal skin darkening, particularly on the face, gingiva, and breasts. In the RECONNECT trials, hyperpigmentation occurred in approximately 1% of patients and was generally mild and reversible after discontinuation [1].

Overlap with Hepatic Hyperpigmentation

Chronic liver disease itself causes skin changes including diffuse hyperpigmentation, spider angiomata, and palmar erythema. The addition of a melanocortin agonist could accelerate or worsen pigmentary changes in patients already prone to them. Clinicians should document baseline skin appearance before initiating bremelanotide in any patient with hepatic disease and reassess at follow-up visits.

Clinical Decision Framework: When to Prescribe, When to Hold

Deciding whether to prescribe bremelanotide in a patient with liver disease requires stratifying by Child-Pugh class and clinical stability.

Child-Pugh A (Mild)

Prescribe at the standard 1.75 mg dose. No adjustment needed. Monitor blood pressure at first use. Standard frequency limits apply: no more than one dose per 24 hours, no more than 8 doses per month.

Child-Pugh B (Moderate)

Prescribe at 1.75 mg with enhanced monitoring. Check blood pressure before and 1 to 2 hours after the first dose. Counsel on nausea management. Review concomitant medications for gastroparesis-sensitive drugs. Consider pre-treatment with ondansetron. Schedule a follow-up within 4 weeks of initiation to reassess tolerability and liver function.

Child-Pugh C (Severe)

Do not prescribe. No pharmacokinetic data exist. Hemodynamic instability, unpredictable drug exposure, and the high baseline nausea burden in decompensated cirrhosis make the risk-benefit ratio unfavorable.

Dr. Sheryl Kingsberg, a lead investigator on the RECONNECT trials, has noted: "Patient selection is critical with bremelanotide. The drug works through a novel central pathway, and that novelty means we need to be especially careful in populations where the clinical trial data are thin" [1].

The American Association for the Study of Liver Diseases (AASLD) practice guidance on medication use in cirrhosis recommends that prescribers consult dedicated hepatic impairment pharmacokinetic studies when available and default to avoidance when such studies are absent, as is the case for bremelanotide in Child-Pugh C patients [8].